New York State Teachers Retirement System Grows Stock Position in Illumina, Inc. $ILMN

New York State Teachers Retirement System lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,638 shares of the life sciences company’s stock after buying an additional 4,002 shares during the period. New York State Teachers Retirement System’s holdings in Illumina were worth $19,627,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares during the period. Generali Asset Management SPA SGR raised its stake in shares of Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after buying an additional 7,574 shares during the period. Elo Mutual Pension Insurance Co purchased a new position in shares of Illumina during the 3rd quarter valued at approximately $2,319,000. Caprock Group LLC purchased a new position in shares of Illumina during the 3rd quarter valued at approximately $1,479,000. Finally, Nordea Investment Management AB lifted its position in shares of Illumina by 148.6% during the 3rd quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock valued at $3,024,000 after buying an additional 19,519 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ILMN shares. Canaccord Genuity Group decreased their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday. JPMorgan Chase & Co. increased their target price on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. Piper Sandler decreased their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Finally, UBS Group reiterated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $130.13.

Illumina Price Performance

Shares of Illumina stock opened at $135.78 on Friday. The business has a 50 day simple moving average of $125.68 and a two-hundred day simple moving average of $126.65. Illumina, Inc. has a 12 month low of $73.86 and a 12 month high of $155.53. The stock has a market capitalization of $20.63 billion, a P/E ratio of 24.69, a PEG ratio of 2.60 and a beta of 1.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.71% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm earned $0.97 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts predict that Illumina, Inc. will post 5.15 EPS for the current fiscal year.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with non‑GAAP EPS $1.15 vs. $1.05 consensus and revenue $1.09B (up 4.8% y/y); management raised FY‑2026 EPS guidance to $5.15–$5.30 and updated revenue targets — this underpins the stock strength. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Management cited surging NovaSeq X demand and growth in clinical sequencing as a primary driver of revenue momentum — a product‑driven acceleration that supports durable top‑line growth. ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
• Positive Sentiment: Board authorized an additional $1.5B in share repurchases, expanding buybacks alongside better margins — a capital‑return boost that can support near‑term EPS and investor sentiment. Illumina lifts 2026 outlook and expands share buybacks
• Neutral Sentiment: Analysts are updating models: JPMorgan raised its price target to $125 but kept a “neutral” rating, reflecting mixed views on near‑term upside despite operational improvements. Analyst Price Target Update
• Negative Sentiment: Even with the PT bump, the $125 target implies a mid‑single‑digit to low‑double‑digit downside from current levels — a reminder that some analysts still see limited valuation upside and room for multiple compression. Analyst Price Target Update

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.